About Eclipse Bio
Eclipse Bio is a company based in San Diego (United States) founded in 2017 by Eric Van Nostrand, Gene Yeo, Alexander Shishkin, and Peter Chu.. Eclipse Bio has raised $18.91 million across 5 funding rounds from investors including ARE, HHS and Phoenix Venture Partners. The company has 14 employees as of December 31, 2020. Eclipse Bio offers products and services including eMERGE, eVERSE, End-Seq, and eRibo Pro. Eclipse Bio operates in a competitive market with competitors including Abingdon Health, Spear Bio, Olink, Virtue Diagnostics and Correlia Biosystems, among others.
- Headquarter San Diego, United States
- Employees 14 as on 31 Dec, 2020
- Founders Eric Van Nostrand, Gene Yeo, Alexander Shishkin, Peter Chu
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eclipse Bioinnovations, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$18.91 M (USD)
in 5 rounds
-
Latest Funding Round
$4.91 M (USD), Series A
Nov 05, 2025
-
Investors
ARE
& 3 more
-
Employee Count
14
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eclipse Bio
Eclipse Bio offers a comprehensive portfolio of products and services, including eMERGE, eVERSE, End-Seq, and eRibo Pro. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for mRNA and saRNA development challenges
Provides datasets for AI model training in drug discovery
Assay to map unique regulatory regions of RNA
Measures transcription and translation in RNA biology
Unlock access to complete
Unlock access to complete
Funding Insights of Eclipse Bio
Eclipse Bio has successfully raised a total of $18.91M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $4.91 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $4.9M
-
First Round
First Round
(20 Sep 2017)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2025 | Amount | Series A - Eclipse Bio | Valuation |
investors |
|
| Jul, 2024 | Amount | Grant - Eclipse Bio | Valuation |
investors |
|
| Mar, 2022 | Amount | Series A - Eclipse Bio | Valuation | Alexandria |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Eclipse Bio
Eclipse Bio has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, HHS and Phoenix Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm funding transformative technologies
|
Founded Year | Domain | Location | |
|
Tech and life Science focused early stage VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eclipse Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Eclipse Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eclipse Bio Comparisons
Competitors of Eclipse Bio
Eclipse Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abingdon Health, Spear Bio, Olink, Virtue Diagnostics and Correlia Biosystems, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of immunoassays for diagnostic purposes
|
|
| domain | founded_year | HQ Location |
Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers
|
|
| domain | founded_year | HQ Location |
Provider of products and services for human protein biomarker research and development
|
|
| domain | founded_year | HQ Location |
An in vitro assay platform is provided for diagnostic solutions.
|
|
| domain | founded_year | HQ Location |
Correlia Biosystems is focused on protein quantification technology.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eclipse Bio
Frequently Asked Questions about Eclipse Bio
When was Eclipse Bio founded?
Eclipse Bio was founded in 2017.
Where is Eclipse Bio located?
Eclipse Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Eclipse Bio?
Peter Chu is the current CEO of Eclipse Bio. They have also founded this company.
Is Eclipse Bio a funded company?
Eclipse Bio is a funded company, having raised a total of $18.91M across 5 funding rounds to date. The company's 1st funding round was a Series A of $14M, raised on Sep 20, 2017.
How many employees does Eclipse Bio have?
As of Dec 31, 2020, the latest employee count at Eclipse Bio is 14.
What does Eclipse Bio do?
Eclipse Bio was founded in 2017 in San Diego, United States, within the biotechnology sector. Operations focus on the eCLIP-seq method, a high-throughput sequencing approach that enhances crosslinking and immunoprecipitation for RNA binding protein target identification. Components utilized include cancer cell lines such as HEK293T and K562, human iPSC stem cells, differentiated cells like neurons and cardiomyocytes, and tissues from brain and heart.
Who are the top competitors of Eclipse Bio?
Eclipse Bio's top competitors include Abingdon Health, Spear Bio and Olink.
What products or services does Eclipse Bio offer?
Eclipse Bio offers eMERGE, eVERSE, End-Seq, and eRibo Pro.
Who are Eclipse Bio's investors?
Eclipse Bio has 4 investors. Key investors include ARE, HHS, Phoenix Venture Partners, and IGlobe Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.